Close Sidebar
Nordic Life Science
Now Reading
Orion’s Darolutamide receives approval for additional prostate cancer indication in Japan
Search for content, post, videos
Search for content, post, videos

Orion’s Darolutamide receives approval for additional prostate cancer indication in Japan

February 27, 2023
1685 Views
Orion R and D
The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer. The MHLW approval is based on the positive results from the Phase III ARASENS tria
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.

Malin Otmani

Related Posts

Susan Galbraith
May 6, 2022

AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi, in combination with standard-of-care chemotherapy, has been accepted and granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer (BTC). The Food and Drug Administration (Already a subscriber Login You have read all your free articles,…

Renée Aguiar-Lucander Photo Jann Lipka
August 29, 2022

Calliditas Therapeutics announced in July that the European Commission (EC) has granted conditional marketing authorization for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCAlready a subscriber Login You have read all your free…

April 9, 2015

Prior to the Enzymatics annual general meeting scheduled for April 21, the nominating committee proposed the re-election of three members of the board of directors and the election of another three. Proposed for re-election are Christian W. Jansson, Marianne Dicander and Anders Jungbeck. New candidAlready a subscriber Login You have read…

Björn Sjöstrand
October 13, 2020

Scandinavian Biopharma has entered into an agreement with the United States Army Medical Research Acquisition Activity (USAMRAA) to support the production and development of the vaccine, with the long-term goal of preventing bacterial diarrhoea in war fighters. In April this year, SBH announced tAlready a subscriber Login You have read…